CAHPharmaceutical distribution and medical products
Cardinal Health
- Price
- $272.81
- Discount category
- Close to intrinsic value
- Analysts
- Bullish
- Next earnings
- Feb 4 · · estimated
- Pick status
- Research only
In short
- Thesis
- Investors pay a premium for the fast profit growth and the buybacks of Cardinal Health, and only strong growth after fiscal 2027 with a final CVS Health agreement can earn it.
- Gap
- Slow. Only several more years of profit growth in drug distribution, with a final CVS Health agreement, can earn the premium.
Company guidance: Non-GAAP diluted EPS of $12.80 to $13.00 for fiscal year 2027 (, Q1 fiscal 2027 earnings release (8-K))
Price history
About
Cardinal Health is one of the largest distributors of medicines in the United States. It also makes and distributes medical and laboratory products, supplies home-health products, runs nuclear pharmacies and gives freight and data services. It reports two segments, Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution, and three other businesses: Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight Logistics.
In Q1 of fiscal 2027 (the three months to September 30, 2026), revenue was $67.5 billion: $62.6 billion from Pharmaceutical and Specialty Solutions, $3.2 billion from Global Medical Products and Distribution and the rest from the other businesses. Revenue was $254.2 billion in fiscal 2026. Its fiscal year ends on June 30.
The shares trade on the New York Stock Exchange. The head office is in Dublin, Ohio. Jason Hollar is Chief Executive Officer.
Thesis
Cardinal Health trades above its intrinsic value because investors pay for fast profit growth, large buybacks and renewed contracts with large customers. In Q1 of fiscal 2027, non-GAAP diluted EPS rose 28% to $3.26, and the company raised its fiscal 2027 guidance to $12.80 to $13.00. For the shares to earn this price, three things must be true. Pharmaceutical and Specialty Solutions must grow its profit by 10% to 12% in fiscal 2027, as guided, and keep growing after that.
The binding letter of intent with CVS Health, which extends the distribution agreement to June 30, 2032, must become a final agreement on the current scope. The profit of Global Medical Products and Distribution, which fell 28% in Q1, must recover. The Q2 fiscal 2027 report, expected in early February 2027, is the next test. Slower growth in drug distribution or new opioid claims can push the shares down.
Checkpoints
- Nov 5, 2026PassedQ1 fiscal 2027 results and guidanceNon-GAAP EPS growth and a confirmed or higher fiscal 2027 guidance pass; a guidance cut fails.Outcome: Non-GAAP diluted EPS rose 28% to $3.26, and the company raised its guidance to $12.80 to $13.00.
- Feb 4, 2027 · est.PendingQ2 fiscal 2027 resultsPharmaceutical and Specialty Solutions profit growth of 10% or more and a confirmed guidance pass; less fails.
- Q3 2027 · est.PendingFinal distribution agreement with CVS HealthA signed agreement through June 30, 2032 on the current scope passes; a smaller scope or no agreement fails.
Recent events
- November 5, 2026Cardinal Health reported Q1 fiscal 2027 results. Revenue rose 5% to $67.5 billion, GAAP diluted EPS rose 27% to $2.38 and non-GAAP diluted EPS rose 28% to $3.26. The company raised its fiscal 2027 guidance for non-GAAP diluted EPS to $12.80 to $13.00 from $12.40 to $12.60, and it completed a $500 million share repurchase program.
- October 1, 2026Cardinal Health signed a binding letter of intent to extend its distribution agreement with CVS Health through June 30, 2032, with the current scope of distribution services.
- August 11, 2026Cardinal Health reported fiscal 2026 results. Revenue rose 14% to $254.2 billion, and non-GAAP diluted EPS rose 37% to $11.26, or 33% to $10.95 without a one-time tariff refund. The board approved $5.0 billion of new share repurchases, for a total authorization of $6.4 billion, and the company renewed its distribution contract with Kroger.
Show 1 older eventHide older events
- March 23, 2026Patricia A. Hemingway Hall became Chair of the Board after Gregory B. Kenny retired. She has been a director since 2013.
Latest news and filings
- Last earnings
- November 5, 2026 (8-K on sec.gov)
- Next earnings
- Expected about February 4, 2027. The company has not confirmed the date.
- 10-QQuarterly report for the period ended Sep 30, 2026Filed cah-20260930
- 8-KEarnings release and Investor disclosureFiled Press release and exhibits
- 8-KInvestor disclosureFiled cah-20261001
- 10-KAnnual report for the period ended Jun 30, 2026Filed cah-20260630
- 8-KEarnings release and Investor disclosureFiled Press release and exhibits
- 8-KNew material agreement and End of a material agreementFiled cah-20260807
- 8-KChange of directors or officersFiled cah-20260804
- 10-QQuarterly report for the period ended Mar 31, 2026Filed cah-20260331
- 8-KEarnings release and Investor disclosureFiled Press release and exhibits
- 8-KChange of directors or officers and Investor disclosureFiled cah-20260317
Risks
Bull case: Non-GAAP EPS rose 28% in Q1 fiscal 2027, and a final CVS Health agreement to 2032 with $6.4 billion of buyback authorization can keep profit per share growing.
- A few large customers, such as CVS Health, give a large part of revenue. The CVS Health renewal is a letter of intent until the parties sign the final agreement.
- Cardinal Health had $3.9 billion accrued at September 30, 2026 for national opioid litigation settlements, with most payments through 2038. Other opioid lawsuits continue.
- Changes to drug prices in the United States can reduce the fees and margins of distributors.
- Global Medical Products and Distribution has a low margin: segment profit was $33 million on revenue of $3.2 billion in Q1 fiscal 2027. Tariffs, freight costs and exchange rates can cut it more.
- Shareholders' equity is negative, a deficit of $2,866 million at September 30, 2026. Large losses or payments can reduce the room for more buybacks.
Key statistics
- Market cap
- $63B
- Shares of Oct 31, 2026
- Dividend yield
- 0.8%
- Current annual rate, at the price of Nov 21, 2026
- P/E (trailing)
- 35.3
- Price of Nov 21, 2026
- EPS (trailing)
- $7.73
- 12 months to Sep 30, 2026
- 52-week range
- $180.45 – $286.29
- To Nov 12, 2026
- Beta
- 0.53
- Vs S&P 500, 5 years monthly, to Oct 30, 2026
- Average volume
- 1.7M
- 3 months, to Nov 12, 2026
Check the numbers:ExchangeGoogle FinanceYahoo FinanceSEC filings
Balance sheet
- Cash
- $5.3B
- Debt
- $8.8B
- Net debt
- $3.6B
Cash against debt
debt covered by cashnet debt $3.6B
When the debt is due
Cardinal Health funds itself mainly with payables to suppliers, bonds and cash flow. At September 30, 2026, cash and equivalents were $5,264 million, and debt was $8,815 million: $1,886 million due within a year and $6,929 million of long-term obligations. The total shareholders' deficit was $2,866 million. The company had $3.9 billion accrued for national opioid litigation settlements, and it expects most of the payments through 2038. In Q1 of fiscal 2027, operating cash flow was $1,398 million. The company paid $385 million for opioid litigation, including the sixth annual payment of $366 million under the National Opioid Settlement Agreement, bought back $500 million of shares and paid $126 million of dividends. The quarterly dividend is $0.5158 per share. The company added $1.0 billion of uncommitted revolving credit facilities in November 2026.
Dividends
- Dividend yield
- 0.8% (current annual rate, at today’s price of $272.81)
- Paid per share
- $2.054 in the last 12 months (4 payments)
- Current annual rate
- $2.064 ($0.516 × 4 a year)
- Payout ratio
- 21% of the last fiscal year’s earnings (the year that ended June 30, 2026)
- Latest ex-dividend date
- October 1, 2026, $0.516 per share
Dividends per share by year
| 2016 | $1.734 | |
|---|---|---|
| 2017 | $1.835 | |
| 2018 | $1.89 | |
| 2019 | $1.919 | |
| 2020 | $1.939 | |
| 2021 | $1.959 | |
| 2022 | $1.979 | |
| 2023 | $1.999 | |
| 2024 | $1.513 | |
| 2025 | $2.034 |
2024 has 3 payments (a usual year has 4): a payment date moved across the year end.
From 2020 to 2025, the dividend grew by about 1.0% a year. From 2016 to 2025, the dividend grew by about 1.8% a year.
Source: company filings and market data, read on November 13, 2026. The ex-dividend date is the first day a buyer no longer gets the next payment.
Questions about Cardinal Health
What does Cardinal Health do?
Cardinal Health is one of the largest distributors of medicines in the United States. It also makes and distributes medical and laboratory products, supplies home-health products, runs nuclear pharmacies and gives freight and data services. Its market cap is $63B at the current price of $272.81.
When does Cardinal Health report earnings next?
This is an estimate: Cardinal Health may report on February 4, 2027. It last reported results on November 5, 2026.
Is Cardinal Health stock below its intrinsic value?
Cardinal Health stock is close to intrinsic value. This is general information, not advice.
What changed recently at Cardinal Health?
The latest update is from November 5, 2026. Cardinal Health reported Q1 fiscal 2027 results.
What are the main risks for Cardinal Health?
A few large customers, such as CVS Health, give a large part of revenue. Cardinal Health had $3.9 billion accrued at September 30, 2026 for national opioid litigation settlements, with most payments through 2038. Changes to drug prices in the United States can reduce the fees and margins of distributors.
How much debt and cash does Cardinal Health have?
At September 30, 2026, Cardinal Health had $8.8B of debt and $5.3B of cash.
Does Cardinal Health pay a dividend?
Yes. The current annual dividend of Cardinal Health is $2.064 per share. That is a dividend yield of 0.8% at the current price of $272.81. In the last 12 months, it paid $2.054 per share (0.8%). The latest ex-dividend date was October 1, 2026.
Valuation against peers
| Company | P/E, last 4 quarters | EV/EBITDA, last year | Free cash flow yield, last year | 10-year average P/E |
|---|---|---|---|---|
| CAHCardinal Health | 35.3x | n/a | 7.2% | 33.9x |
| MDLNMedline | n/a | 17.9x | 2.7% | n/a |
| CORCencora | 25.2x | 20.0x | 5.0% | 23.9x |
| SOLVSolventum | 94.9x | n/a | -0.1% | n/a |
| JNJJohnson & Johnson | 41.1x | n/a | 3.0% | 21.7x |
| Peer median | 41.1x | 19.0x | 2.8% | n/a |
- CAH trades at 35.3x earnings, 14% below the peer median of 41.1x.
- Its free cash flow yield is 7.2%, 4.3 points above the peer median of 2.8%.
- Against its own history, the P/E is 4% above its average of 33.9x over 8 profitable years.
The peers are the companies on this site most like CAH. The multiples come from company filings and today's price, and P/E uses GAAP diluted EPS. Picks shows no analyst forecast: the only look ahead is a company's own EPS guidance, where it gives one. EV/EBITDA is left out for banks, insurers and real estate companies. This is general information, not advice.
Similar companies
- BDXBecton DickinsonShares: Weight-loss drugs, Tariffs and trade, Regulation and courts
- Intrinsic value
- Close to intrinsic value
- Gap
- Can close
- MDLNMedlineShares: Tariffs and trade, Regulation and courts
- Intrinsic value
- Below intrinsic value
- Gap
- Can close
- CORCencoraShares: Regulation and courts, Weight-loss drugs
- Intrinsic value
- Close to intrinsic value
- Gap
- Can close
- NVONovo NordiskShares: Weight-loss drugs, Regulation and courts
- Intrinsic value
- Close to intrinsic value
- Gap
- Can close
- AZNAstraZenecaShares: Regulation and courts, Tariffs and trade
- Intrinsic value
- Close to intrinsic value
- Gap
- Can close
Loading your notes…
Read it all? Star CAH or pass, then go on to the next one.